| Schedule of Segment Reporting Information |
The measure of profit for the segment is net loss and consisted of the following for the three and six months ended June 30, 2026, and 2025: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | (in thousands) | 2026 | | 2025 | | 2026 | | 2025 | | Revenue from external customers | $ | 8,806 | | | $ | 1,973 | | | $ | 11,514 | | | $ | 30,780 | | | Compensation expense, excluding stock-based compensation, stock appreciation rights compensation expense and severance expense | 4,820 | | | 9,903 | | | 9,900 | | | 21,473 | | | Direct research and development program expenses (X4P-001, mavorixafor) | 10,428 | | | 9,413 | | | 20,824 | | | 17,825 | | | Other segment items (a) | 9,715 | | | 8,398 | | | 17,188 | | | 16,941 | | | Net loss (measure of segment profit) | $ | (16,157) | | | $ | (25,741) | | | $ | (36,398) | | | $ | (25,459) | |
(a) Other segment items primarily include cost of revenue, non-compensation departmental costs within sales, general and administrative departments, certain unallocated external costs within research and development, stock-based compensation expense, stock appreciation rights compensation expense, severance expense, other income (expense), and provision for income taxes.
|